• Je něco špatně v tomto záznamu ?

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

SE. Inzucchi, KF. Docherty, L. Køber, MN. Kosiborod, FA. Martinez, P. Ponikowski, MS. Sabatine, SD. Solomon, S. Verma, J. Bělohlávek, M. Böhm, CE. Chiang, RA. de Boer, M. Diez, A. Dukát, CEA. Ljungman, O. Bengtsson, AM. Langkilde, M. Sjöstrand,...

. 2021 ; 44 (2) : 586-594. [pub] 20201218

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026108

Grantová podpora
RE/18/6/34217 British Heart Foundation - United Kingdom

OBJECTIVE: The sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. This report explores the effect of dapagliflozin on incident type 2 diabetes (T2D) in the cohort without diabetes enrolled in the trial. RESEARCH DESIGN AND METHODS: The subgroup of 2,605 patients with heart failure and reduced ejection fraction (HFrEF), no prior history of diabetes, and an HbA1c of <6.5% at baseline was randomized to dapagliflozin 10 mg daily or placebo. In this exploratory analysis, surveillance for new-onset diabetes was accomplished through periodic HbA1c testing as part of the study protocol and comparison between the treatment groups assessed through a Cox proportional hazards model. RESULTS: At baseline, the mean HbA1c was 5.8%. At 8 months, there were minimal changes, with a placebo-adjusted change in the dapagliflozin group of -0.04%. Over a median follow-up of 18 months, diabetes developed in 93 of 1,307 patients (7.1%) in the placebo group and 64 of 1,298 (4.9%) in the dapagliflozin group. Dapagliflozin led to a 32% reduction in diabetes incidence (hazard ratio 0.68, 95% CI 0.50-0.94; P = 0.019). More than 95% of the participants who developed T2D had prediabetes at baseline (HbA1c 5.7-6.4%). Participants who developed diabetes in DAPA-HF had a higher subsequent mortality than those who did not. CONCLUSIONS: In this exploratory analysis among patients with HFrEF, treatment with dapagliflozin reduced the incidence of new diabetes. This potential benefit needs confirmation in trials of longer duration and in people without heart failure.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026108
003      
CZ-PrNML
005      
20211026133213.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.2337/dc20-1675 $2 doi
035    __
$a (PubMed)33355302
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Inzucchi, Silvio E $u Section of Endocrinology, Yale University School of Medicine, New Haven, CT silvio.inzucchi@yale.edu
245    10
$a Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF / $c SE. Inzucchi, KF. Docherty, L. Køber, MN. Kosiborod, FA. Martinez, P. Ponikowski, MS. Sabatine, SD. Solomon, S. Verma, J. Bělohlávek, M. Böhm, CE. Chiang, RA. de Boer, M. Diez, A. Dukát, CEA. Ljungman, O. Bengtsson, AM. Langkilde, M. Sjöstrand, PS. Jhund, JJV. McMurray, DAPA-HF Investigators and Committees
520    9_
$a OBJECTIVE: The sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. This report explores the effect of dapagliflozin on incident type 2 diabetes (T2D) in the cohort without diabetes enrolled in the trial. RESEARCH DESIGN AND METHODS: The subgroup of 2,605 patients with heart failure and reduced ejection fraction (HFrEF), no prior history of diabetes, and an HbA1c of <6.5% at baseline was randomized to dapagliflozin 10 mg daily or placebo. In this exploratory analysis, surveillance for new-onset diabetes was accomplished through periodic HbA1c testing as part of the study protocol and comparison between the treatment groups assessed through a Cox proportional hazards model. RESULTS: At baseline, the mean HbA1c was 5.8%. At 8 months, there were minimal changes, with a placebo-adjusted change in the dapagliflozin group of -0.04%. Over a median follow-up of 18 months, diabetes developed in 93 of 1,307 patients (7.1%) in the placebo group and 64 of 1,298 (4.9%) in the dapagliflozin group. Dapagliflozin led to a 32% reduction in diabetes incidence (hazard ratio 0.68, 95% CI 0.50-0.94; P = 0.019). More than 95% of the participants who developed T2D had prediabetes at baseline (HbA1c 5.7-6.4%). Participants who developed diabetes in DAPA-HF had a higher subsequent mortality than those who did not. CONCLUSIONS: In this exploratory analysis among patients with HFrEF, treatment with dapagliflozin reduced the incidence of new diabetes. This potential benefit needs confirmation in trials of longer duration and in people without heart failure.
650    _2
$a benzhydrylové sloučeniny $x terapeutické užití $7 D001559
650    12
$a diabetes mellitus 2. typu $x komplikace $x farmakoterapie $x epidemiologie $7 D003924
650    _2
$a glukosidy $7 D005960
650    12
$a srdeční selhání $x farmakoterapie $x epidemiologie $7 D006333
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a tepový objem $7 D013318
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Docherty, Kieran F $u BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K
700    1_
$a Køber, Lars $u Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
700    1_
$a Kosiborod, Mikhail N $u Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO
700    1_
$a Martinez, Felipe A $u National University of Cordoba, Cordoba, Argentina
700    1_
$a Ponikowski, Piotr $u Wroclaw Medical University, Wroclaw, Poland
700    1_
$a Sabatine, Marc S $u TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA
700    1_
$a Solomon, Scott D $u Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA
700    1_
$a Verma, Subodh $u Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
700    1_
$a Bělohlávek, Jan $u 2nd Department of Medicine - Cardiovascular Medicine, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Böhm, Michael $u Internal Medicine Clinic III (Böhm), Saarland University Medical Center, Homburg/Saar, Germany
700    1_
$a Chiang, Chern-En $u General Clinical Research Center, and Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan
700    1_
$a de Boer, Rudolf A $u Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
700    1_
$a Diez, Mirta $u Division of Cardiology, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
700    1_
$a Dukát, Andre $u Fifth Department of Internal Medicine, Comenius University in Bratislava, Bratislava, Slovakia
700    1_
$a Ljungman, Charlotta E A $u Department of Molecular and Clinical Medicine and Cardiology, Sahlgrenska Academy, Gothenburg, Sweden
700    1_
$a Bengtsson, Olof $u AstraZeneca, Gothenburg, Sweden
700    1_
$a Langkilde, Anna Maria $u AstraZeneca, Gothenburg, Sweden
700    1_
$a Sjöstrand, Mikaela $u AstraZeneca, Gothenburg, Sweden
700    1_
$a Jhund, Pardeep S $u BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K
700    1_
$a McMurray, John J V
710    2_
$a DAPA-HF Investigators and Committees
773    0_
$w MED00001380 $t Diabetes care $x 1935-5548 $g Roč. 44, č. 2 (2021), s. 586-594
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33355302 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133219 $b ABA008
999    __
$a ok $b bmc $g 1714964 $s 1146615
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 44 $c 2 $d 586-594 $e 20201218 $i 1935-5548 $m Diabetes care $n Diabetes Care $x MED00001380
GRA    __
$a RE/18/6/34217 $p British Heart Foundation $2 United Kingdom
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace